Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 12/20 | 0.57 |
| ▸ | IDH1 | O75874 | 3/20 | 0.44 |
| ▸ | IDH2 | P48735 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21977581 | 0.87 | IDH1 (0.62) | TGFBR1IDH1IDH2CYP1A2 | |
| SCHEMBL17812902 | 0.85 | TGFBR1 (0.59) | TGFBR1CYP1A2ABCB1ABCC1ABCG2 | |
| SCHEMBL16391713 | 0.83 | ABCG2 (0.60) | ABCB1ABCC1ABCG2 | |
| SCHEMBL17812899 | 0.82 | CYP1A2 (0.52) | TGFBR1IDH1IDH2CYP1A2ABCB1 | |
| SCHEMBL16391808 | 0.81 | TGFBR1 (0.46) | TGFBR1IDH1IDH2CYP1A2TGFBR2 | |
| SCHEMBL17812903 | 0.81 | TGFBR1 (0.46) | TGFBR1IDH1IDH2CYP1A2TGFBR2 | |
| SCHEMBL16392137 | 0.80 | IDH1 (0.43) | TGFBR1IDH1IDH2CYP1A2ABCB1 | |
| SCHEMBL16391950 | 0.80 | TGFBR1 (0.47) | TGFBR1IDH1IDH2CYP1A2ABCB1 | |
| SCHEMBL21977577 | 0.80 | TGFBR1 (0.47) | TGFBR1IDH1IDH2CYP1A2ABCB1 | |
| SCHEMBL17812908 | 0.80 | ABCG2 (0.48) | TGFBR1IDH1IDH2CYP1A2TGFBR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160158230-A1 | 2,4- OR 4,6-DIAMINOPYRIMIDINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | SERVIER PHARMACEUTICALS LLC | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158230-A1 | 2,4- OR 4,6-DIAMINOPYRIMIDINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | IDH2, IDH3B, IDH3A | TGFBR1 3893/4885IDH1 4/4885IDH2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.